Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics Post published:July 29, 2021 Post category:Press Release
Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer Post published:July 15, 2021 Post category:Press Release
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board Post published:June 23, 2021 Post category:Press Release
Nova Mentis Organizes Autism Data Bank in North America Post published:April 20, 2021 Post category:Press Release
Nova Mentis Establishes Serotonin Research Centre Post published:March 31, 2021 Post category:Press Release
Nova Mentis Announces Promising Research Results Post published:March 29, 2021 Post category:Press Release
Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market Post published:March 10, 2021 Post category:Press Release
Nova Mentis Launches Autism Microbiome Study in the United States Post published:March 3, 2021 Post category:Press Release
Nova Mentis Autism Clinical Study Approved by Institutional Review Board Post published:February 25, 2021 Post category:Press Release